885069-14-7

Basic information

• Product Name: N-(6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]thiazol-2-yl)acetamide
• Synonyms: N-(6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]thiazol-2-yl)acetamide;AcetaMide,N-[6-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)-2-benzothiazolyl]-
• CAS NO: 885069-14-7
• Molecular Formula: C₁₅H₁₉BN₂O₃S
• Molecular Weight: 318
• Mol File: 885069-14-7.mol
• Article Data: 16

Chemical Properties

• Appearance: /
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: N-(6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]thiazol-2-yl)acetamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]thiazol-2-yl)acetamide(885069-14-7)
• EPA Substance Registry System: N-(6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]thiazol-2-yl)acetamide(885069-14-7)

Safety Data

• Hazardous Substances Data: 885069-14-7(Hazardous Substances Data)

Usage

General Description

N-(6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]thiazol-2-yl)acetamide is a chemical compound that belongs to the class of acetamides. It contains a benzothiazole moiety with a boron-containing functional group attached to it. N-(6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]thiazol-2-yl)acetamide has potential applications in medicinal chemistry as a building block for the synthesis of pharmaceuticals or bioactive molecules. The presence of the boron-containing group makes it useful for cross-coupling reactions, which are widely used in organic synthesis. Additionally, the benzothiazole moiety is found in various pharmacologically active compounds, suggesting potential biological activities for N-(6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]thiazol-2-yl)acetamide. Further exploration of its properties and potential applications is warranted.

Upstream product

• 15864-32-1 2-amino-6-bromobenzothiazole 
• 73183-34-3 bis(pinacol)diborane 
• 16628-26-5 N-(6-bromo-1,3-benzothiazol-2-yl)acetamide 
• 106-40-1 4-bromo-aniline 

Downstream Products

• 1112980-20-7 N-(6-(1H-indazol-4-yl)-1,3-benzothiazol-2-yl)acetamide 
• 1112982-55-4 N-(6-(6-(2-fluorophenylsulfonyl)pyridin-2-yl)benzo[d]thiazol-2-yl)acetamide 
• 1112979-81-3 N-(6-(2-((4-methoxyphenyl)sulfonyl)-1,3-thiazol-5-yl)-1,3-benzothiazol-2-yl)acetamide 
• 1112979-86-8 N-(6-(6-((4-fluorophenyl)sulfonyl)-2-pyridinyl)-1,3-benzothiazol-2-yl)acetamide 
• 1112979-89-1 N-(6-(6-((4-methoxyphenyl)sulfonyl)-2-pyridinyl)-1,3-benzothiazol-2-yl)acetamide 
• 1112979-92-6 N-(6-(2-amino-1,3-benzothiazol-6-yl)-2-pyridinyl)benzenesulfonamide 
• 1112979-95-9 N-(6-(6-(methyl((4-methylphenyl)sulfonyl)amino)-2-pyridinyl)-1,3-benzothiazol-2-yl)acetamide 
• 1112980-18-3 N-(6-(2-((4-fluorophenyl)sulfonyl)-1,3-thiazol-4-yl)-1,3-benzothiazol-2-yl)acetamide 
• 1112980-86-5 N-(2-chloro-5-(2-acetylaminobenzo[d]thiazol-6-yl)pyridin-3-yl)-4-fluorophenylsulfonamide 
• 1112980-87-6 N-(6-(6-chloro-5-(4-methoxyphenylsulfonamido)pyridin-3-yl)benzo[d]thiazol-2-yl)acetamide 
• 1112981-20-0 N-(6-(5-(((4-methylphenyl)sulfonyl)amino)-3-pyridinyl)-1,3-benzothiazol-2-yl)acetamide 
• 1112981-46-0 N-(6-(5-(methyl((4-(trifluoromethyl)phenyl)sulfonyl)amino)-3-pyridinyl)-1,3-benzothiazol-2-yl)acetamide 
• 1112981-53-9 N-(6-(6-(methyl((3-methylphenyl)sulfonyl)amino)-2-pyridinyl)-1,3-benzothiazol-2-yl)acetamide 
• 1112981-89-1 N-(6-(5-(((4-(1-hydroxyethyl)phenyl)sulfonyl)amino)-3-pyridinyl)-1,3-benzothiazol-2-yl)acetamide 

Relevant articles and documents

HETEROARYL COMPOUNDS AS INHIBITORS OF NECROSIS, COMPOSITION AND APPLICATION THEREOF

The present disclosure provides heteroaryl compounds of formulas (I), (Ia) and (Ib), processes for their preparation, pharmaceutical compositions containing them, and their use in the treatment of diseases and disorders, arising from or related to necrosi

MECHANISTIC TARGET OF RAPAMYCIN SIGNALING PATHWAY INHIBITORS AND THERAPEUTIC APPLICATIONS THEREOF

Selective mTOR inhibitors of formulas (I)-(III), processes for their preparation, pharmaceutical compositions containing them, and their use in the treatment of diseases and disorders, arising from abnormal cell growth, functions, or behaviors mediated by an mTOR kinase and/or one or more PI3K enzyme, are provided. Such diseases and disorder include cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders and neurological disorders.

Structural basis for isoform selectivity in a class of benzothiazole inhibitors of phosphoinositide 3-kinase γ

Phosphoinositide 3-kinase γ (PI3Kγ) is an attractive target to potentially treat a range of disease states. Herein, we describe the evolution of a reported phenylthiazole pan-PI3K inhibitor into a family of potent and selective benzothiazole inhibitors. U